Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $455
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $440 to $455.
Related Posts
ExxonMobil Starts Operations At Baytown Advanced Recycling Facility
ExxonMobil today announced successful startup of one of the largest advanced recycling facilities in North America. The facility at the company's integrated manufacturing complex in Baytown, Texas, uses proprietary
Lockheed Martin, F-35 Joint Program Office Ink £147M Contract To Support UK’s F-35 Fleet
Lockheed Martin Corp (NYSE:LMT) and the F-35 Joint Program Office (JPO) signed the Lightning Air System National Capability Enterprise (LANCE) 23-27…
Major Bank Profits Surge More Than Expected In Q1, Drawing Customer Deposits From Smaller Players
Major U.S. financial institutions JP Morgan Chase & Co. (NYSE: JPM), Wells Fargo & Company (NYSE: WFC), BlackRock, Inc. (NYSE: